GIMHAE, South Korea, Nov. 18, 2026 /PRNewswire/ -- South Korean healthcare company IREONA Inc. participated in MEDICAL JAPAN in October 2026, presenting its IREONA smart care series and the LENEX sleep product alongside an investor relations (IR) presentation. The exhibition provided an opportunity to introduce the company's approach to supporting more comfortable and independent daily living.
As aging populations increase demand for care, IREONA is exploring technologies to help caregivers manage daily care tasks and respond to users' needs. The IREONA series is being developed for a range of care settings, with functions tailored to individual applications rather than uniformly applied across all products.
For certain bed-care applications under development, the company is investigating the use of multiple sensors, including pressure sensors, together with AI-based analysis. These approaches are intended to detect changes in bed conditions and provide caregivers with information about the bed environment and hygiene-related factors. If successfully developed, they could help reduce repetitive observation tasks and support more timely responses.
Its development approach also considers the dignity of people receiving care and the working conditions of those providing it. IREONA is also studying possible medical device applications related to pressure ulcer prevention. Any products requiring medical device authorization would be subject to the relevant regulatory procedures before commercialization. Separately, the company is exploring technologies that analyze sleep posture and movement patterns to support sleep-environment management, as well as potential uses of sensing, AI and robotics in other care settings.
Alongside the smart care series, IREONA introduced LENEX, a pillow made with thermoplastic polyester elastomer (TPEE). Drawing on the material's elasticity and shape-recovery properties, LENEX is designed with comfort, usability and ease of maintenance in mind. Its development also considers the physical pressure experienced by people who spend extended periods lying down and aims to support a sleep environment that may be helpful in pressure ulcer care.
The IREONA series and LENEX reflect the company's view that technology should complement, not replace, human care. IREONA seeks to address practical needs experienced by users, families and caregivers while helping individuals maintain independence where possible.
Through its participation in MEDICAL JAPAN and its IR presentation, IREONA introduced its development direction to an international audience and explored potential opportunities in overseas markets. The company plans to continue developing healthcare technologies and products for diverse care and everyday living environments.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
IREONA Inc. Showcases Smart Care Series and Delivers IR Presentation at MEDICAL JAPAN 2026
The seventh symposium in Gangneung, South Korea, featured clinical research on REJURAN® polynucleotides and a behind-the-scenes look at how the products are made
GANGNEUNG, South Korea, Nov. 18, 2026 /PRNewswire/ -- PharmaResearch, the Korean pharmaceutical company behind the globally recognized skin booster REJURAN, brought together more than 750 medical professionals from 64 countries for its seventh PharmaResearch Global Symposium (PGS), held Oct. 26–28 in Gangneung, South Korea. The event gave clinicians working in aesthetic and regenerative medicine a chance to compare their experiences with polynucleotides (PN) and polydeoxyribonucleotides (PDRN) and discuss emerging approaches to treatment.
The program began with a look at how PharmaResearch sources and processes the raw material behind its PN and PDRN products. At a Korea Fisheries Resources Agency center, attendees saw how raw material is obtained from wild salmon and prepared for manufacturing. The tour continued at PharmaResearch's Gangneung plant, where they followed the material through processing, production and quality control.
The scientific program turned to how REJURAN PN, developed using PharmaResearch's proprietary DNA Optimizing Technology (DOT®), is being studied and used in clinical practice. Across four sessions, clinicians discussed the evidence behind REJURAN, approaches to treatment and ways to improve the patient experience.
Safety was one focus of the discussion. U.S. physician Dr. Suneel Chilukuri reviewed the safety profile of REJURAN PN, and Drs. Atchima Suwanchinda and Thanya Techapichetvanich from Thailand shared recent research on PN across several treatment areas. The program also examined what may be happening at the tissue level, with Australian physician Dr. Steven Liew discussing what histological findings suggest about how PN may support skin repair.
Clinical cases brought those discussions into the treatment room. Dr. Yuri Yogya shared cases from his practice in Indonesia involving the lip area, while Japan's Dr. Soichiro Morikawa discussed his experience combining PN with other treatments.
South Korean actress Kim Sejeong, a global ambassador for REJURAN and REJURAN COSMETICS, also attended the symposium.
"It was an honor to be part of an event that brought together so many clinicians and researchers from around the world," Kim said. "I hope to bring REJURAN's message about caring for your natural beauty and feeling confident in yourself to more people around the world."
"The symposium gave clinicians from around the world a chance to review the clinical evidence and safety data for DOT® PN and discuss how that research could inform future treatment protocols," a PharmaResearch spokesperson said. "We'll continue to expand these exchanges in South Korea and internationally to help advance clinical practice in medical aesthetics."
About PharmaResearch
PharmaResearch is a pioneering South Korean biopharmaceutical company dedicated to enhancing quality of life through regenerative medicine. Its portfolio spans medicines, medical devices, cosmetics and health supplements, built around its core DOT® PDRN and DOT® PN technologies, which are protected by multiple patents. PharmaResearch is headquartered in Gangneung, South Korea.
The company is behind REJURAN, its globally recognized PN-based skin booster available in more than 50 countries, and REJURAN COSMETICS, its premium derma-cosmetic brand.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
PharmaResearch Global Symposium Draws More Than 750 Clinicians From 64 Countries